Efficacy and safety of Infliximab in systemic sarcoidosis according to GenPhenReSa organ-involvement phenotype: a retrospective study of 55 patients

Infliximab is currently recommended as a third-line treatment for refractory sarcoidosis. Data in function of clinical phenotype are currently lacking. We evaluated patients’ characteristics and responses to infliximab according to their GenPhenReSa cluster. We evaluated clinical and biological characteristics of patients diagnosed with sarcoidosis who received infliximab between September 2008 and April 2019 at our centre. Fifty-five patients (median disease duration, 87 months) received infliximab: 48 (87 Infliximab is highly effective in patients with CNS (group 1) and liver (group 2) organ-predominant sarcoidosis. Infliximab is poorly effective in patients with musculoskeletal-cutaneous involvement (group 3). Infectious episodes are frequent and can be severe in this immunocompromised population.